Abstract: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Abstract: The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin diseases such as atopic dermatitis. An external preparation for skin which contains one or more compounds selected from the group consisting of 5-aminolevulinic acid, its salt and a derivative of them; and an iron compound; as active components, is used.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release fumarate esters are described.

Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.

Abstract: Formulations, kits, and methods for rebuilding the disulfide bonds in keratin found in hair, skin, or nails. Hair that is damaged due to a hair coloring treatment and/or other reducing treatment, such as during a permanent wave, can be treated with the formulations containing one or more active agents. The formulations may be applied subsequent to a hair coloring treatment or simultaneously with a hair coloring treatment. Use of the active agent formulations during a permanent wave treatment prevents the reversion of the hair to its previous state, for at least one week, preferably at least three months, more preferably at least one year, most preferably greater than one year, after one or more than one application of the formulation. Application of the active agent formulation to skin or nails can help repair damaged disulfide bonds due to natural wear and tear or natural aging.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release fumarate esters are described.

Abstract: Compositions and methods for treating or preventing fungal infections of the nail are provided. The topical composition includes the use of chlorine dioxide, chlorite salts, benzoyl peroxide, an alpha hydroxy acid, antifungal and antibiotic agents. Also provided is a heat-generating device for use in treating at least one nail infected with fungus and a toe sock device.

Abstract: A bi-phasic pharmaceutical composition for oral administration including one or more solid active ingredient containing particles dispersed within a semi-solid carrier formulation. The solid particles include a coating with pH-triggered drug release properties and the semi-solid carrier formulation is formulated at a pH that is different than the pH at which the active ingredient release properties of the coating are triggered. Also described is a delivery system for delivery of the bi-phasic pharmaceutical composition including the bi-phasic pharmaceutical composition described above and a dispenser pouch formed from flexible laminate sheets. Further, a process for manufacturing the two-phase pharmaceutical delivery system is described including the filling the bi-phasic pharmaceutical composition into flexible dispenser pouches, which allows the patient to squeeze and dispense the contents of the package directly into the oral cavity.

Abstract: Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection and surrounding skin. A method for the transdermal treatment or prevention of fungal toenails or fingernails or foot infections with an antifungal agent is also disclosed, the method comprising adhesively securing to a dorsal site of an infected palm or foot a pressure-sensitive adhesive matrix patch device for a time sufficient to deliver an effective amount of the antifungal agent to an area of infection.

Abstract: The present invention provides durable, natural looking, non-invasive compositions that exhibit desired aesthetic qualities. Specifically, the compositions can be used for therapeutic treatments, including treatments of wounds and headaches. The invention pertains, at least in part, to therapeutic formulations for application to the skin that comprise a) a reactive reinforcing component; and b) a cross-linking component; in which the cross-linking component facilitates in situ formation of a film over the skin.

Abstract: Disclosed is a microcapsule including a core having an oxidizable active (OA), the outer part of said core being in a solid form, and a water insoluble coating obtained from an encapsulating agent (EA), with the coating surrounding said core. In particular, there is disclosed a microcapsule wherein the EA is water soluble or organic solvent, in particular ethanol, soluble, or a microcapsule wherein said EA is an agent, the water solubility of which is pH-dependent. In particular, the core does not consist in or comprise a metal oxide, and the coating does not comprise a disintegrant, in particular sodium starch glycolate. Also disclosed is a process for preparing the microcapsules.

Abstract: The present invention relates to new aqueous microemulsions containing organic pesticide compounds of limited water-solubility and to their use for plant protection, including seed and crop protection, and protection or non-living material. The aqueous microemulsions comprise a) at least one pyrethroid compound P; b) at least one organic solvent, selected from compounds of the formula I R1—(O-Alk)m-O—C(O)R2 (I) wherein m is 1, 2 or 3, R1 is H, C1-C6-alkyl or C(O)R3, R2 is hydrogen or C1-C4-alkyl, which may be unsubstituted or substituted with OH, Alk is C2-C6-alkylene, and R3 is hydrogen or C1-C4-alkyl, which may be unsubstituted or substituted with OH; c) at least one surfactant; and d) water.

Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase, having at least one silicone surfactant, and a method for preparing emulsions capable of delivering active resveratrol to the skin.

Abstract: The present invention relates to novel compositions for treating seeds. Moreover, the present invention is directed to the production of these compositions and the uses of these compositions.

Abstract: The present invention comprises compositions and methods for providing antimicrobial compositions. The antimicrobial compositions comprise gel delivery vehicles comprising stabilized silver, wherein ionic silver is provided to a site for antimicrobial purposes. Methods of making and using such compositions are taught, including application of the silver-containing gel compositions to wounds, burns, abrasions, cuts, surgical incision, sites where skin or organ integrity has been breached, and other sites to supply an antimicrobial environment.

Abstract: A silver composition comprising silver sulfate, methods of making antimicrobial articles, particularly packaged antimicrobial articles, methods of whitening antimicrobial articles, and packaged antimicrobial articles.

Abstract: The present invention relates to a bifunctional material which comprises copper and which is capable of storing nitric oxide (NO), as well as catalytically producing nitric oxide from a suitable precursor. The material typically includes a zeolite and the copper may be part of, or separate from the zeolite. In this manner the material may include a single bifunctional material; that is, a material which is capable of both storing NO and catalytically producing NO, such as Cu-MFI or Cu-X. Alternatively the material may include at least two components, a first component to store NO, such as a zeolite Zn-LTA, and a further component including Cu(I), such as Cu2O, to catalytically produce NO from a suitable precursor. The bifunctional material may be used in a pharmaceutical, neutraceutical or cosmetic preparation, or comprised in a medical article, a cosmetic and/or personal hygiene product.

Abstract: Use of a compound of formula (I) or a 3-enol C1-4 alkanoate ester thereof in the manufacture of a medicament for the intermittent treatment of a condition of a human or non-human mammal in which said mammal has an abnormally high serum concentration of an adrenal hormone: Wherein R1, R2, R5, and R6 are the same or different and each is hydrogen or C1 to 4? alkyl; R3 is hydrogen C1 to 4? alkyl, C1 to 4? alkenyl or C1 to 4? alkynyl; R4 is hydroxy, C1 to 4? alkanoyloxy, a group of formula (II) or (III) Wherein R7 is (CH2)n, where n is an integer of from 0 to 4, R8 is hydrogen, C1 to 4? alkyl, hydroxy or NH2 and R9 and R10 are the same or different and each is hydrogen or C1 to 4? Alkyl; or R3 and R4 together are oxo, ethylenedioxy or propylenedioxy. The invention has practical benefits for the treatment of man and other animals with diseases associated with abnormal production of adrenal steroids.

Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

Abstract: A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills. A dissolvable medication administration bag may be constructed in accordance with a pill crusher pouch embodiment into which a pill is placed prior to being crushed and subsequently the whole of pouch and the crushed pill contents are dissolved into a liquid, e.g. a beverage, as a means of reducing health hazards associated with current pill crushing practices such as inadvertent direct contact and aerosolization with subsequent inhalation of the crushed medication.